AAAAAA
Results:
1-12
|
Results: 12
Authors:
Weeber, M
Klein, H
de Jong-van den Berg, LTW
Vos, R
Citation: M. Weeber et al., Using concepts in literature-based discovery: Simulating Swanson's Raynaud-fish oil and migraine-magnesium discoveries, J AM SOC IN, 52(7), 2001, pp. 548-557
Authors:
Wieringa, NF
Vos, R
de Graeff, PA
Citation: Nf. Wieringa et al., Comparative trials in registration files of cardiovascular drugs: Comparator drugs and dosing schemes., PHARM WORLD, 23(1), 2001, pp. 28-30
Authors:
Wieringa, NF
Denig, P
de Graeff, PA
Vos, R
Citation: Nf. Wieringa et al., Assessment of new cardiovascular drugs - Relationships between considerations, professional characteristics, and prescribing, INT J TE A, 17(4), 2001, pp. 559-570
Authors:
Vos, R
Lux, M
Xu, K
Fyen, W
Kenens, C
Conard, T
Mertens, P
Heyns, M
Hatcher, Z
Hoffman, M
Citation: R. Vos et al., Removal of submicrometer particles from silicon wafer surfaces using HF-based cleaning mixtures, J ELCHEM SO, 148(12), 2001, pp. G683-G691
Authors:
Sarnelli, G
Vos, R
Cuomo, R
Janssens, J
Tack, J
Citation: G. Sarnelli et al., Reproducibility of gastric barostat studies in healthy controls and in dyspeptic patients, AM J GASTRO, 96(4), 2001, pp. 1047-1053
Authors:
Vos, R
Willems, DL
Citation: R. Vos et Dl. Willems, Technology in medicine: Ontology, epistemology, ethics and social philosophy at the crossroads, THEOR MED B, 21(1), 2000, pp. 1-7
Authors:
Wieringa, NF
Vos, R
Van der Werf, GT
Van der Veen, WJ
De Graeff, PA
Citation: Nf. Wieringa et al., Co-morbidity of 'clinical trial' versus 'real-world' patients using cardiovascular drugs, PHARMA D S, 9(7), 2000, pp. 569-579
Authors:
Wieringa, NF
Vos, R
van der Werf, GT
de Graeff, PA
Citation: Nf. Wieringa et al., Inclusion of patients with comorbidity and comedication in premarketing trials of cardiovascular drugs, DRUG DEV R, 51(3), 2000, pp. 159-168
Authors:
Vos, R
Citation: R. Vos, Global capital flows: Should they be regulated? Foreword by James Tobin., ECON J, 110(461), 2000, pp. F267-F269
Authors:
Mertens, PW
Bearda, T
Houssa, M
Loewenstein, LM
Cornelissen, I
De Gendt, S
Kenis, K
Teerlinck, I
Vos, R
Meuris, M
Heyns, MM
Citation: Pw. Mertens et al., Advanced cleaning for the growth of ultrathin gate oxide, MICROEL ENG, 48(1-4), 1999, pp. 199-206
Authors:
Wieringa, NF
de Graeff, PA
van der Werf, GT
Vos, R
Citation: Nf. Wieringa et al., Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use, EUR J CL PH, 55(7), 1999, pp. 537-544
Authors:
Heyns, MM
Bearda, T
Cornelissen, I
De Gendt, S
Degraeve, R
Groeseneken, G
Kenens, C
Knotter, DM
Loewenstein, LM
Mertens, PW
Mertens, S
Meuris, M
Nigam, T
Schaekers, M
Teerlinck, I
Vandervorst, W
Vos, R
Wolke, K
Citation: Mm. Heyns et al., Cost-effective cleaning and high-quality thin gate oxides, IBM J RES, 43(3), 1999, pp. 339-350
Risultati:
1-12
|